CBLL
Bearish signalScored 2026-10-04 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
CeriBell, Inc.
- Nom
- CeriBell, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NASDAQ
- Capitalisation
- $1.1B
- Employés
- 327
- PDG
- Xingjuan Chao
- Site web
- https://ceribell.com
- Marché
- BWAYCVRXECORLIVNNMTCNPCE
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 113 163 titres (~2 788 323,59 $ US)
- Insiders
- Chao XingjuanTaylor Joseph Michael
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$4,984,916
Avg sell (VWAP, 90d window) $23.50 vs last close $23.48 (-0.1%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$4,415,978 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-15
- Liquidity
- Thin $8,177,553/day · 20d vol
- Last synced
-
2026-10-07 21:10:11
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-01 | Woo Raymond | Sell · S · 10b5-1 | 4,887 | $24.38 | $119,145 | Form 4 |
| 2026-09-15 | Blumberg Scott | Sell · S · 10b5-1 | 846 | $25.00 | $21,150 | Form 4 |
| 2026-09-15 | Chao Xingjuan | Sell · S · 10b5-1 | 20,846 | $25.03 | $521,775 | Form 4 |
| 2026-09-08 | Foehr David | Sell · S · 10b5-1 | 7,500 | $24.25 | $181,875 | Form 4 |
| 2026-09-08 | Woo Raymond | Sell · S · 10b5-1 | 4,887 | $24.33 | $118,901 | Form 4 |
| 2026-09-02 | Blumberg Scott | Sell · S · 10b5-1 | 652 | $25.00 | $16,300 | Form 4 |
| 2026-09-02 | Chao Xingjuan | Sell · S · 10b5-1 | 39,540 | $24.61 | $973,079 | Form 4 |
| 2026-08-24 | Foehr David | Sell · S · 10b5-1 | 859 | $23.95 | $20,573 | Form 4 |
| 2026-08-21 | Blumberg Scott | Sell · S | 1,521 | $24.02 | $36,534 | Form 4 |
| 2026-08-21 | Chao Xingjuan | Sell · S | 6,068 | $24.02 | $145,753 | Form 4 |
| 2026-08-21 | Foehr David | Sell · S · 10b5-1 | 993 | $24.02 | $23,852 | Form 4 |
| 2026-08-21 | Manni Joseph S. | Sell · S | 1,361 | $24.02 | $32,691 | Form 4 |
| 2026-08-21 | Woo Raymond | Sell · S | 1,979 | $24.02 | $47,536 | Form 4 |
| 2026-08-19 | Blumberg Scott | Sell · S · 10b5-1 | 33,512 | $25.03 | $838,805 | Form 4 |
| 2026-08-19 | Chao Xingjuan | Sell · S · 10b5-1 | 31,415 | $25.03 | $786,317 | Form 4 |
| 2026-08-18 | Blumberg Scott | Sell · S · 10b5-1 | 990 | $25.00 | $24,750 | Form 4 |
| 2026-08-18 | Chao Xingjuan | Sell · S · 10b5-1 | 2,199 | $25.00 | $54,975 | Form 4 |
| 2026-08-13 | Taylor Joseph Michael | Sell · S | 13,095 | $23.40 | $306,423 | Form 4 |
| 2026-08-03 | Chao Xingjuan | Sell · S · 10b5-1 | 39,000 | $18.32 | $714,480 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-04 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
CBLL presents a deeply concerning risk profile: despite a meaningful earnings catalyst (33% revenue growth, FDA clearance, institutional buying), the company's structural financial distress — persistent negative…
The first sentence of the analysis written for CBLL on 2026-10-04 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Unavailable or mixed. Current ratio 9.73 · operating margin -66% — readings disagree
Suggested stop 20.80, nearest stored support minus 0.5 ATR(11.4% under the last close). Reward/risk to the next stored resistance is 0.29. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.9% | 86.7% | 84.4% | 82.9% | |
| Ebit Margin | -57.8% | -58.8% | -60.5% | -137.2% | |
| Ebitda Margin | -56.3% | -57.0% | -58.6% | -135.3% | |
| Operating Profit Margin | -65.6% | -60.7% | -66.4% | -139.0% | |
| Pretax Profit Margin | -60.0% | -61.8% | -65.1% | -143.4% | |
| Continuous Operations Profit Margin | -60.0% | -61.8% | -65.1% | -143.4% | |
| Net Profit Margin | -60.0% | -61.8% | -65.1% | -143.4% | |
| Bottom Line Profit Margin | -60.0% | -61.8% | -65.1% | -143.4% | |
| Current Ratio | 9.730 | 16.727 | 2.406 | 8.090 | |
| Quick Ratio | 9.350 | 16.193 | 2.134 | 7.677 | |
| Solvency Ratio | -1.287 | -1.148 | -0.167 | -0.212 | |
| Cash Ratio | 2.109 | 14.964 | 1.597 | 6.918 | |
| Price To Earnings Ratio | -15.021 | -22.903 | -19.841 | -15.723 | |
| Price To Earnings Growth Ratio | -0.514 | 2.220 | 0.956 | 0.000 | |
| Forward Price To Earnings Growth Ratio | -0.514 | 2.220 | 0.956 | 0.000 | |
| Price To Earnings Diluted Ratio | -15.021 | -22.903 | -19.841 | -15.723 | |
| Price To Earnings Diluted Growth Ratio | -0.514 | 2.220 | 0.956 | 0.000 | |
| Price To Book Ratio | 5.159 | 4.853 | -5.195 | -6.749 | |
| Price To Sales Ratio | 8.998 | 14.177 | 12.893 | 22.495 | |
| Price To Free Cash Flow Ratio | -19.275 | -25.501 | -19.345 | -17.932 | |
| Price To Operating Cash Flow Ratio | -19.638 | -26.476 | -19.997 | -18.221 | |
| Debt To Assets Ratio | 0.114 | 0.097 | 0.241 | 0.211 | |
| Debt To Equity Ratio | 0.143 | 0.115 | -0.127 | -0.211 | |
| Debt To Capital Ratio | 0.125 | 0.103 | -0.145 | -0.267 | |
| Long Term Debt To Capital Ratio | 0.113 | 0.093 | 0.000 | -0.173 | |
| Financial Leverage Ratio | 1.261 | 1.179 | -0.525 | -1.001 | |
| Working Capital Turnover Ratio | 0.479 | 0.558 | 0.902 | 0.000 | |
| Operating Cash Flow Ratio | -2.127 | -2.698 | -1.350 | -3.244 | |
| Operating Cash Flow Sales Ratio | -0.458 | -0.535 | -0.645 | -1.235 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.019 | 1.038 | 1.034 | 1.016 | |
| Debt Service Coverage Ratio | -26.551 | -18.736 | -1.904 | -8.546 | |
| Interest Coverage Ratio | -30.901 | -19.934 | -14.319 | -22.471 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | -2.464 | -12.801 | |
| Operating Cash Flow Coverage Ratio | -1.832 | -1.596 | -2.053 | -1.756 | |
| Capital Expenditure Coverage Ratio | -53.205 | -26.151 | -29.663 | -62.019 | |
| Dividend Paid And Capex Coverage Ratio | -53.205 | -26.151 | -29.663 | -62.019 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -15.607 | -20.240 | -21.232 | -15.204 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 87.9% | ▲1.2% | ▲2.4% |
| Ebit Margin | -57.9% | ▲0.9% | ▲20.7% |
| Ebitda Margin | -56.3% | ▲0.7% | ▲20.5% |
| Operating Profit Margin | -65.6% | ▼-4.9% | ▲17.3% |
| Pretax Profit Margin | -60.0% | ▲1.8% | ▲22.6% |
| Continuous Operations Profit Margin | -60.0% | ▲1.8% | ▲22.6% |
| Net Profit Margin | -60.0% | ▲1.8% | ▲22.6% |
| Bottom Line Profit Margin | -60.0% | ▲1.8% | ▲22.6% |
| Current Ratio | 9.730 | ▼-6.997 | ▲0.492 |
| Quick Ratio | 9.350 | ▼-6.843 | ▲0.512 |
| Solvency Ratio | -1.287 | ▼-0.139 | ▼-0.583 |
| Cash Ratio | 2.109 | ▼-12.855 | ▼-4.288 |
| Price To Earnings Ratio | -15.021 | ▲7.882 | ▲3.351 |
| Price To Earnings Growth Ratio | -0.514 | ▼-2.734 | ▼-1.180 |
| Forward Price To Earnings Growth Ratio | -0.514 | ▼-2.734 | ▼-1.180 |
| Price To Earnings Diluted Ratio | -15.021 | ▲7.882 | ▲3.351 |
| Price To Earnings Diluted Growth Ratio | -0.514 | ▼-2.734 | ▼-1.180 |
| Price To Book Ratio | 5.159 | ▲0.305 | ▲5.642 |
| Price To Sales Ratio | 8.998 | ▼-5.179 | ▼-5.643 |
| Price To Free Cash Flow Ratio | -19.275 | ▲6.226 | ▲1.238 |
| Price To Operating Cash Flow Ratio | -19.637 | ▲6.839 | ▲1.446 |
| Debt To Assets Ratio | 0.114 | ▲0.016 | ▼-0.052 |
| Debt To Equity Ratio | 0.143 | ▲0.029 | ▲0.163 |
| Debt To Capital Ratio | 0.125 | ▲0.022 | ▲0.171 |
| Long Term Debt To Capital Ratio | 0.113 | ▲0.020 | ▲0.105 |
| Financial Leverage Ratio | 1.260 | ▲0.081 | ▲1.032 |
| Working Capital Turnover Ratio | 0.479 | ▼-0.079 | ▼-0.006 |
| Operating Cash Flow Ratio | -2.127 | ▲0.571 | ▲0.228 |
| Operating Cash Flow Sales Ratio | -0.458 | ▲0.077 | ▲0.260 |
| Free Cash Flow Operating Cash Flow Ratio | 1.019 | ▼-0.019 | ▼-0.008 |
| Debt Service Coverage Ratio | -26.551 | ▼-7.815 | ▼-12.617 |
| Interest Coverage Ratio | -30.901 | ▼-10.966 | ▼-8.994 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲3.816 |
| Operating Cash Flow Coverage Ratio | -1.832 | ▼-0.236 | ▼-0.023 |
| Capital Expenditure Coverage Ratio | -53.205 | ▼-27.053 | ▼-10.445 |
| Dividend Paid And Capex Coverage Ratio | -53.205 | ▼-27.053 | ▼-10.445 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -15.607 | ▲4.633 | ▲2.464 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Market cap | $801.4M | $927.8M | $583.1M | $583.1M | |
| Enterprise value | $783.2M | $755.4M | $562.8M | $533.1M | |
| EV / Sales | 8.79x | 11.54x | 12.45x | 20.57x | |
| EV / Op. cash flow | -19.19x | -21.56x | -19.30x | -16.66x | |
| EV / Free cash flow | -18.84x | -20.76x | -18.67x | -16.39x | |
| EV / EBITDA | -15.61x | -20.24x | -21.23x | -15.20x | |
| Net debt / EBITDA | 0.36x | 4.62x | 0.77x | 1.43x | |
| Current ratio | 9.73x | 16.73x | 2.41x | 8.09x | |
| Income quality | 0.76x | 0.87x | 0.99x | 0.86x | |
| Graham net-net | $4 | $5 | -$5 | -$4 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 103.7% | 105.2% | 107.7% | 104.5% | |
| Working capital | $167.5M | $204.3M | $30.4M | $69.9M | |
| Invested capital | $172.7M | $208.7M | $34.1M | $73.8M | |
| Return on assets | -27.3% | -17.9% | -50.0% | -43.0% | |
| Operating ROA | -27.7% | -27.9% | -41.3% | 0.0% | |
| Return on tangible assets | -27.4% | -17.9% | -50.0% | -43.0% | |
| Return on equity | -34.4% | -21.2% | 26.2% | 43.0% | |
| Return on invested capital | -32.9% | -18.6% | -60.3% | -45.2% | |
| Return on capital employed | -33.1% | -18.7% | -80.5% | -47.0% | |
| Earnings yield | -6.7% | -4.4% | -5.1% | -6.4% | |
| Free cash flow yield | -5.2% | -3.9% | -5.2% | -5.6% | |
| Capex / Op. cash flow | -1.9% | -3.8% | -3.4% | -1.6% | |
| Capex / Depreciation | -114.5% | 117.4% | 116.1% | 103.8% | |
| Capex / Sales | 0.9% | 2.0% | 2.2% | 2.0% | |
| SG&A / Sales | 132.0% | 126.7% | 130.9% | 193.9% | |
| R&D / Sales | 21.5% | 20.7% | 19.9% | 27.9% | |
| Stock comp / Sales | 13.7% | 8.3% | 5.9% | 30.6% | |
| Intangibles / Total assets | 0.4% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 62d | 61d | 64d | 75d | |
| Days payables outstanding | 96d | 48d | 38d | 35d | |
| Operating cycle | 308d | 352d | 367d | 410d | |
| Cash conversion cycle | 212d | 304d | 330d | 375d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-02 BlackRock Inc. Acquires New Holdings in CeriBell, Inc. $CBLL BlackRock Inc. bought a new position in shares of CeriBell, Inc. (NASDAQ: CBLL) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,936,093 shares of the company''s stock, valued at approximately $37,657,000. BlackRock Inc. owned approximately 5.10% of CeriBell as
- 2026-08-27 Bank of America Corp DE Has $5.86 Million Position in CeriBell, Inc. $CBLL Bank of America Corp DE boosted its holdings in CeriBell, Inc. (NASDAQ: CBLL) by 15.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 319,837 shares of the company''s stock after acquiring an additional 42,340 shares during the
- 2026-08-12 CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push CeriBell NASDAQ: CBLL outlined its plans to expand its brainwave-monitoring platform beyond seizure detection, pointing to new products for delirium, pediatric patients and eventually stroke as it continues to build its hospital customer base.
- 2026-08-11 CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript
- 2026-08-10 Here''s What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings Although the revenue and EPS for CeriBell, Inc. (CBLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 2026-08-10 CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.38 per share a year ago.
- 2026-08-10 CeriBell Q2 Earnings Call Highlights CeriBell NASDAQ: CBLL reported second-quarter 2026 revenue growth of 33% as increased utilization at existing hospital accounts and continued customer additions supported results. The company also raised its full-year revenue outlook and outlined plans to commercially launch its delirium-monitoring solution later this year.
- 2026-08-10 Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review SUNNYVALE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for two new AI algorithm enhancements integrated directly into its existing cloud-based Neurology Portal: Epileptiform Abnormality Detection and Artifact Reduction.1 These new capabilities expand the clinical utility of the Ceribell Point-of-Care (POC) brain monitoring system, providing neurologists and bedside practitioners with an enhanced toolset for rapid, high-confidence electroencephalogram (EEG) assessment.
- 2026-08-03 Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System Incremental NTAP Reimbursement Stands to Broaden Access to First-of-Its-Kind Dual Seizure and Delirium Monitoring Platform Incremental NTAP Reimbursement Stands to Broaden Access to First-of-Its-Kind Dual Seizure and Delirium Monitoring Platform
- 2026-07-29 Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O''Keefe SUNNYVALE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the appointments of Thomas “Tom” West and Sharon O''Keefe to its Board of Directors.